2674-0338

Frontiers in Drug Discovery

Frontiers Media SA

Health Score

0 Good

Metadata coverage

Abstract
ORCID
References
License

Extended metadata coverage

Informational — signals of interoperability and funding across the corpus. Not part of the health score.

Funding

Funder
Award / grant

Affiliation & institutional identifiers

Affiliation
ROR ID

Update policy

Update policy

Your prioritized action plan

Ordered by how many DOIs each fix touches — start here, not with every error at once.

1

Attach ORCID iDs across 177 articles

ORCID iDs strengthen author disambiguation and institutional reporting.

High impact177 DOIs
2

Add abstracts to 21 articles

Abstracts are what surface your work in Google Scholar, Dimensions, and OpenAlex.

Low impact21 DOIs
3

Deposit reference lists for 9 records

Deposited references power Crossref's Cited-by links between your articles and the literature.

Low impact9 DOIs

DOIs for this ISSN

Showing the top 5 of 177 DOIs, ordered by correction priority.

# Title Missing Priority Citations
1 Grand Challenges of Computer-Aided Drug Design: The Road Ahe… (10.3389/fddsv.2021.728551)
Abstract ORCID
82.17 43
2 Post-Pandemic Drug Discovery and Development: Facing Present… (10.3389/fddsv.2021.728469)
Abstract ORCID
61.52 16
3 The grand challenge of discovering new cardiovascular drugs (10.3389/fddsv.2022.1027401)
Abstract ORCID
60.21 15
4 Drug discovery and development: introduction to the general… (10.3389/fddsv.2023.1201419)
ORCID
57.90 206
5 Integrative computational approaches for discovery and evalu… (10.3389/fddsv.2024.1362456)
ORCID
48.98 90
6 How drug repurposing can advance drug discovery: challenges… (10.3389/fddsv.2024.1460100)
ORCID
48.61 87
7 The (misleading) role of animal models in drug development (10.3389/fddsv.2024.1355044)
ORCID
47.02 75
8 Introduction to small molecule drug discovery and preclinica… (10.3389/fddsv.2023.1314077)
ORCID
46.73 73
9 Current advances in our understanding of circular RNA (circR… (10.3389/fddsv.2022.983030)
Abstract ORCID
45.15 7
10 Alternative therapeutics to control antimicrobial resistance… (10.3389/fddsv.2024.1385460)
ORCID
45.15 63
11 On the biologically relevant chemical space: BioReCS (10.3389/fddsv.2025.1674289)
Abstract ORCID
45.15 7
12 Deep Learning Prediction of Adverse Drug Reactions in Drug D… (10.3389/fddsv.2021.768792)
ORCID
43.51 54
13 Machine learning in toxicological sciences: opportunities fo… (10.3389/fddsv.2024.1336025)
ORCID
37.63 31
14 Is Covid-19 Severity Associated With ACE2 Degradation? (10.3389/fddsv.2021.789710)
ORCID
36.56 28
15 Deep Machine Learning for Computer-Aided Drug Design (10.3389/fddsv.2022.829043)
ORCID
35.78 26
16 Editorial: Advances in anti-malarial drug discovery (10.3389/fddsv.2023.1335842)
Abstract References ORCID
35.78 2
17 Editorial: Pharmacokinetics modeling in the Artificial Intel… (10.3389/fddsv.2025.1636070)
Abstract References ORCID
35.78 2
18 Addressing Antibiotic Failure—Beyond Genetically Encoded Ant… (10.3389/fddsv.2022.892975)
ORCID
34.04 22
19 AI-driven innovation in antibody-drug conjugate design (10.3389/fddsv.2025.1628789)
ORCID
34.04 22
20 In silico immunogenicity assessment for sequences containing… (10.3389/fddsv.2022.952326)
ORCID
33.56 21
21 Furin and COVID-19: Structure, Function and Chemoinformatic… (10.3389/fddsv.2022.899239)
ORCID
33.06 20
22 Artificial intelligence for antiviral drug discovery in low… (10.3389/fddsv.2022.1013285)
ORCID
31.97 18
23 Coumarin-1,2,3-triazole hybrids as leading-edge anticancer a… (10.3389/fddsv.2022.1072448)
ORCID
31.97 18
24 Developing Small-Molecule Inhibitors of Protein-Protein Inte… (10.3389/fddsv.2022.898035)
ORCID
31.97 18
25 Design and Synthesis of Brain Penetrant Glycopeptide Analogu… (10.3389/fddsv.2021.818003)
ORCID
31.38 17
26 Metal-antimicrobial peptides combo: promising weapons to com… (10.3389/fddsv.2024.1440378)
ORCID
30.76 16
27 Editorial: Insights in silico methods and artificial intelli… (10.3389/fddsv.2022.1126955)
Abstract ORCID
30.10 3
28 Nanobodies: COVID-19 and Future Perspectives (10.3389/fddsv.2022.927164)
ORCID
30.10 15
29 A machine learning-based virtual screening for natural compo… (10.3389/fddsv.2022.954911)
ORCID
29.40 14
30 From drugs to targets: Reverse engineering the virtual scree… (10.3389/fddsv.2022.969983)
ORCID
29.40 14
31 FAIR data management: what does it mean for drug discovery? (10.3389/fddsv.2023.1226727)
ORCID
29.40 14
32 Identification of natural compounds as potential inhibitors… (10.3389/fddsv.2025.1525533)
ORCID
29.40 14
33 Harnessing the Potential of Human Pluripotent Stem Cell-Deri… (10.3389/fddsv.2021.773424)
ORCID
28.65 13
34 How artificial intelligence enables modeling and simulation… (10.3389/fddsv.2022.1019706)
ORCID
27.85 12
35 Artificial intelligence platform, RADR®, aids in the discove… (10.3389/fddsv.2022.1033395)
ORCID
27.85 12
36 Enhanced utility of AI/ML methods during lead optimization b… (10.3389/fddsv.2022.1074797)
ORCID
27.85 12
37 A review on dynamics of permeability-glycoprotein in efflux… (10.3389/fddsv.2024.1363364)
ORCID
27.85 12
38 Novel and emerging therapies in pulmonary arterial hypertens… (10.3389/fddsv.2022.1022971)
ORCID
26.98 11
39 The critical role of mode of action studies in kinetoplastid… (10.3389/fddsv.2023.1185679)
ORCID
26.98 11
40 The role of physicochemical and topological parameters in dr… (10.3389/fddsv.2024.1424402)
ORCID
26.98 11
41 Oxidized phospholipids are biomarkers, drug targets, and dru… (10.3389/fddsv.2022.1043708)
ORCID
26.03 10
42 Peptide-Based Strategies Against SARS-CoV-2 Attack: An Updat… (10.3389/fddsv.2022.899477)
ORCID
26.03 10
43 The importance of good practices and false hits for QSAR-dri… (10.3389/fddsv.2023.1237655)
ORCID
26.03 10
44 Applying artificial intelligence to accelerate and de-risk a… (10.3389/fddsv.2024.1339697)
ORCID
26.03 10
45 AI-accelerated therapeutic antibody development: practical i… (10.3389/fddsv.2024.1447867)
ORCID
26.03 10
46 The landscape of nature-derived antimalarials-potential of m… (10.3389/fddsv.2022.1065231)
ORCID
25.00 9
47 The Prospects of Monte Carlo Antibody Loop Modelling on a Fa… (10.3389/fddsv.2022.908870)
ORCID
25.00 9
48 In silico identification of potential inhibitors of acyl car… (10.3389/fddsv.2023.1087008)
ORCID
25.00 9
49 Yin-yang in drug discovery: rethinking de novo design and de… (10.3389/fddsv.2023.1222655)
ORCID
25.00 9
50 State-of-the-art strategies to prioritize Mycobacterium tube… (10.3389/fddsv.2023.1254656)
ORCID
25.00 9